

Editorial: Drug Metabolism and Toxicology

Raju Bandu* and Kwang Pyo Kim

Department of Applied Chemistry, College of Applied Science, Kyung Hee University, Yongin City, 446-701, Republic of Korea

*Corresponding author: Raju Bandu, Department of Applied Chemistry, College of Applied Science, Kyung Hee University, Yongin City, 446-701, Republic of Korea, Tel: +82-10-4042-8806; E-mail: raju.bandu@gmail.com

Received date: June 15, 2016; Accepted date: June 16, 2016; Published date: June 20, 2016

Copyright: © 2016 Bandu R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Editorial

A drug metabolism study is an important aspect of the early drug discovery and development process [1,2]. In order to improve the understanding of drug efficacy and safety characteristics, it is desirable to investigate the drug metabolism in animals or humans [3,4]. These metabolism studies involve metabolic stability, cytochrome P-450 (CYP-450) induction or inhibition and metabolite identification. As drugs are xenobiotics to living organisms, CYP-450 biotransform them to less toxic, less active and more hydrophilic forms in order to enhance their excretion in urine [5,6]. However, metabolism can lead to formation of active metabolites, reactive or other toxic metabolites. Identification of reactive or toxic metabolites is essential in the drug discovery and development process to optimize lead compounds for further development and to avoid the toxicity, and helps to modify the structure by means of chemical transformations [4,7,8]. The information generated in the early discovery phase of metabolite identification can be used to identify lead compounds and undesirable metabolic products followed by optimization of pharmacokinetic and safety profiles. These metabolism studies are generally carried out by employing *in vitro* and *in vivo* systems [8] followed by using modern analytical techniques. Liquid chromatography-mass spectrometry (LC-MS) is the most popular and versatile analytical technique which has been widely used for the identification of trace levels of drugs and their metabolites in various biological matrices due to its high sensitivity [9-12]. Several strategies, such as MS/MS, MSⁿ, on-line hydrogen/deuterium exchange experiments, accurate mass measurements, softwares dedicated to the metabolite prediction (*in silico* tools), chemical derivatization and radio-labeling of parent drugs were used for structural characterization of metabolites [9-15].

References

1. Korfmacher WA, Cox KA, Bryant MS, Veals J, Watkins R, et al. (1997) High Performance Liquid Chromatography (HPLC) in the pharmaceutical analysis Drug Discov Today 2: 532.
2. Kostianen R, Kotiaho T, Kuuranne T, Auriola SJ (2003) Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies. J Mass Spectrom 38: 357-372.
3. Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM (2005) Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx 2: 554-571.
4. Leucuta SE, Vlase L (2006) Curr Clin Pharmacol.
5. Reichel A (2006) The Role of Blood-Brain Barrier Studies in the Pharmaceutical Industry. Curr Drug Metab 7: 183-203.
6. Kostianen R, Kotiaho T, Kuuranne T, Auriola S (2003) Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies. J Mass Spectrom 38: 357-372.
7. Nassar AEF, Kamel AM, Clarimont C (2004) Improving the Decision-Making Process in Structural Modification of Drug Candidates: Reducing Toxicity. Drug Discov Today 9: 1055-1064.
8. Bhogal N, Grindon C, Combes R, Balls M (2005) Toxicity testing: creating a revolution based on new technologies. Trends Biotech 23: 299-307.
9. Raju B, Ramesh M, Borkar RM, Srinivas R, Padiya R, et al. (2012) In vivo metabolic investigation of moxifloxacin using liquid chromatography/electrospray ionization tandem mass spectrometry in combination with online hydrogen/deuterium exchange experiments. Rapid Commun Mass Spectrom 26: 1817-1831.
10. Raju B, Ramesh M, Borkar RM, Padiya R, Banerjee SK, et al. (2012) Identification and structural characterization of in vivo metabolites of ketorolac using liquid chromatography electro-spray ionization tandem mass spectrometry (LC/ESI-MS/MS). J Mass Spectrom 47: 919-931.
11. Bandu R, Ahn HS, Lee JW, Kim YW, Choi SH, et al. (2015) Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometric (LC/ESI-MS/MS) Study for the Identification and Characterization of In Vivo Metabolites of Cisplatin in Rat Kidney Cancer Tissues: Online Hydrogen/Deuterium (H/D) Exchange Study. PLoS One 10: e0134027.
12. Raju B, Jin HK, Jun HM, Pyo KK (2015) A liquid chromatography electro-spray ionization tandem mass spectrometric study (LC/ESI-MS/MS) of in vivo metabolites of cisplatin in rat liver and brain tissues: deuterated experiments. RSC Adv 5: 89951-89958.
13. Liu T, Du F, Wan Y, Zhu F, Xing J (2011) Rapid identification of phase I and II metabolites of artemisinin antimalarials using LTQ-Orbitrap hybrid mass spectrometer in combination with online hydrogen/deuterium exchange technique. J Mass Spectrom 46: 725-733.
14. Holcapek M, Kolárová L, Nobilis M (2008) High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites. Anal Bioanal Chem 391: 59-78.
15. Xiong A, Yang L, He Y, Zhang F, Wang J, et al. (2009) Identification of metabolites of adonifoline, a hepatotoxic pyrrolizidine alkaloid, by liquid chromatography/tandem and high-resolution mass spectrometry. Rapid Commun Mass Spectrom 23: 3907-3916.